Chocolates Recalled From Stores Nationwide

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources.
Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content.
Chocolate products distributed throughout the United States have been recalled.
Weaver Nut Company recalled its semi-sweet chocolate nonpareils with white or Christmas-colored seeds, with specific lot codes, because of potential undeclared milk allergens, the company said in a news release published by the U.S. Food and Drug Administration (FDA) on Wednesday.
"People who have an allergy or severe sensitivity to milk run the risk of serious or life-threatening allergic reactions if they consume the impacted products," it added.
No illnesses have been reported as of the recall date, it said.
Newsweek contacted the company via email for the latest update on Friday.
Stock photo of chocolate.
Stock photo of chocolate.
Getty Images
Why It Matters
Milk is one of the top nine allergens required to be declared by the FDA, and incorrect labeling can put lives at risk, particularly for people with milk allergies or severe sensitivities.
What To Know
The products were distributed through retail and grocery outlets across the U.S., and consumers are urged to check product lot codes and return or discard any affected items.
Weaver's Angela Nolt said the company "is taking all necessary steps to ensure the safety of its products."
The issue was identified after a wholesale customer submitted a complaint regarding discrepancies with product specifications, the FDA said in its release.
Subsequent laboratory testing confirmed the presence of milk proteins in the chocolates, which were labeled as free from milk, it added.
The affected chocolate nonpareils were distributed across the United States and sold through various grocery and retail chains. Weaver Nut Company, based in Pennsylvania, said that the recall is a precautionary measure to safeguard public health.
The FDA release included pictures of the products: (from left) Nonpareil, Semi-Sweet Chocolate (Christmas seeds) and Nonpareils, Semi-Sweet Chocolate (white seeds).
The FDA release included pictures of the products: (from left) Nonpareil, Semi-Sweet Chocolate (Christmas seeds) and Nonpareils, Semi-Sweet Chocolate (white seeds).
Weaver Nut Company
Products and Lot Codes Involved
Item 47518 - Nonpareil, Semi-Sweet Chocolate (Christmas Seeds): Lot numbers 204206, 204207, 204208, 204209, 204212, 224225
Item D2645 - Nonpareils, Semi-Sweet Chocolate (White Seeds): Lot numbers 204214-RL, 204214, 204215, 224221, 224222, 224223, 135215, 135216, 135217, 135220, 135221, 145204, 145205-1, 145207-1, 145210-1
Consumers who purchased the affected items and have a milk allergy or are purchasing for someone who does are urged not to consume them, the recall notice said.
Products should be returned to the place of purchase for a full refund or discarded. Refunds will be provided regardless of package status (opened or unopened), it added.
What Happens Next
Weaver Nut Company and the FDA will continue investigating the cause of the undeclared milk and monitor for any reports of illness. Consumers may contact the company directly for updates or further instructions pending regulatory review.
For further assistance, consumers can contact Chris Westerhoff, customer service manager at Weaver Nut Company, at 717-738-3781, extension 122, or by email at cwesterhoff@weavernut.com, Monday through Friday from 9 a.m. to 4:30 p.m. ET.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Yahoo

38 minutes ago

• Yahoo

Penumbra may gain market share in peripheral embolisation coils with Ruby XL

Penumbra has announced US Food and Drug Administration approval for its Ruby XL system, which includes three coils: the Ruby XL, the POD XL and the Packing Coil XL. The Ruby XL coil is a device used in vascular embolisation, a procedure to block or close off blood vessels, and can be used to frame large aneurysms, while the POD XL is designed for use in high-flow vessels and the Packing Coil XL is designed to adjust to the shape of any vessel up to 70cm in length. All Ruby XL system coils can be delivered through a 0.035-inch diagnostic catheter. The system is expected to enable Penumbra to increase its market share in peripheral embolisation coils, according to leading data and analytics company GlobalData. According to GlobalData's US healthcare facility invoicing database, Penumbra currently holds the majority market share for peripheral embolisation coils. Its new coil system allows for peripheral embolisation procedures to be done on a wider range of aneurysm sizes and in longer vessels. If the Ruby XL coil is widely adopted by physicians, Penumbra may be able to capture half the entire market. The approval of the new coil could put a bigger gap between Penumbra and its competitors in the market. Physicians may choose Ruby XL coils for their procedures in order to gain better control of large aneurysms. The Ruby XL system may come with cost savings for consumers as it delivers more volume per coil than other available coils. The average selling price (ASP) of these coils ranges from approximately $900 to $2,000. Already in the middle of this range with its current coils, Penumbra has a competitive advantage for new products. If they come in with a competitive ASP, Penumbra may displace competitor coils for relevant procedures. Penumbra stands to maintain its market lead and possibly increase its market share as the purchasing of the Ruby XL system begins. GlobalData will continue to monitor market trends as purchasing picks up. It is expected that facilities will begin purchasing these coils in June 2025. "Penumbra may gain market share in peripheral embolisation coils with Ruby XL" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Newsweek

an hour ago

• Newsweek

Map Shows Democrat States Rolling Back Health Care Benefits for Immigrants

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Multiple Democratic-led states, including California, Illinois and Minnesota, have moved to roll back or freeze health care coverage for undocumented immigrants. Others may follow suit. Why It Matters The rollback of state-funded health care access for undocumented immigrants could signal a significant policy shift with national implications. The developments come amid larger debates over immigration and health care policy at a time when state and federal budgets face significant pressures. What To Know These policy reversals have been attributed by the states' Democratic leaders to mounting budget deficits and rising program costs. While coverage for many undocumented residents had been expanded in recent years, governors announced measures to reduce benefits, freeze new enrollments or end programs entirely. Such changes could affect tens of thousands of individuals and counter notions of universal health care, backed by many Democrats, while prompting broader reassessment of similar programs in other states, including Colorado, New York and Washington. Some Democratic-run states are rolling back health care, or considering rolling it back, for undocumented immigrants because of tightened budgets. Some Democratic-run states are rolling back health care, or considering rolling it back, for undocumented immigrants because of tightened budgets. Flourish California: Enrollment Freeze and Possible Benefit Reductions California Governor Gavin Newsom has announced plans to freeze new enrollments in Medi-Cal, the state's Medicaid program, for undocumented adults. Existing recipients would remain covered but could face reduced benefits in the future. Starting in 2027, the state plans to introduce a $100 monthly premium for adults without satisfactory immigration status, attributed to higher-than-expected spending and a multi-billion-dollar budget shortfall. The pause in California is for undocumented adults who haven't already enrolled in Medi-Cal, not people already enrolled. It does not apply to those under age 19, as even those who turn 19 and are on Medi-Cal and remain income eligible will keep their coverage. In May, Newsom said: "We are not cutting or rolling back those that are already enrolled in our Medi-Cal system, we're just capping state has done more than the state of California, no state will continue to more than the state of California by a long shot. That's a point of pride and that's a point of privilege to be governor that's been part of that effort." Under Newsom, California became the first state to offer full-scope Medi-Cal to all low-income adults, regardless of immigration status—expanding access in phases to young adults in 2020, older adults in 2022 and all remaining adults in 2024. "Governor Newsom championed these expansions and remains committed to protecting the immigrant communities who contribute to the fabric and economy of California," Elana Ross, deputy communications director for Newsom's office, told Newsweek on Friday. "He refuses to turn his back on hard-working Californians, especially when it comes to their basic health care needs. "But because of the $16 billion Trump Slump and higher-than-expected health care utilization, the state must take difficult but necessary steps to ensure fiscal stability and preserve the long-term viability of Medi-Cal for all Californians." Proposed adjustments in California's 2025-26 budget would include a $100 monthly premium for certain adults, effective January 1, 2027, and applies to Medi-Cal enrollees age 19 and older with "unsatisfactory immigration status—in line with the average subsidized covered California premium, which is about $135 per month in 2025. The estimated general fund savings would be $2.1 billion by 2028-29. California Governor Gavin Newsom speaks at East Los Angeles College on February 26, 2025, in Monterey Park, California. California Governor Gavin Newsom speaks at East Los Angeles College on February 26, 2025, in Monterey Park, enrollment freeze for full-scope Medi-Cal for undocumented adults, effective no sooner than January 1, 2026, applies only to new adult applicants over 19. Nobody under such a freeze would be kicked off their health care. There would be no impact on limited-scope coverage (emergency, pregnancy services, etc.) and children would remain unaffected. The state, which has previously frozen a publicly sponsored coverage program during difficult budget years, has estimated general-fund savings to be $3.3 billion by 2028-29. Illinois: Full Program Termination Illinois Governor J.B. Pritzker has proposed ending the Health Benefits for Immigrant Adults program as of July 1. The program, launched in 2021, provided state-funded health coverage to more than 30,000 low-income undocumented adults. The decision is a response to higher-than-anticipated costs, aligning with broader deficit reduction efforts. Those previously enrolled will be left without similar coverage options. Newsweek reached out to Pritzker's office for comment. Minnesota: Removal From MinnesotaCare Pritzker specifically related his in-state efforts to what is happening in neighboring states like Minnesota, where Governor Tim Walz said he would sign a bill removing undocumented adults from MinnesotaCare, a state-funded program, by year's end. While coverage for undocumented adults will end, eligibility will continue for undocumented children. The bill reversed a major health policy expansion from 2023. Newsweek reached out to Walz's office for comment. Broader National Trend and Political Debate Congressional Republicans in Colorado, one of seven states offering health care regardless of immigration status, are urging Democratic Governor Jared Polis to rescind Medicaid eligibility for undocumented immigrants. A letter co-signed by Representatives Lauren Boebert, Jeff Crank and Gabe Evans referenced recent rollbacks in California and Minnesota, and cited concerns over rising costs and effects on the state's Medicaid program. The letter, in part, says that each new dollar invested in care for illegal immigrants is a dollar that could go to supporting long-term care for seniors or keeping rural hospitals open. "Congressman Gabe Evans believes Governor Polis should prioritize taxpayer-funded health care for citizens who need it most: single mothers, children and people with disabilities," a spokesperson for Evans told Newsweek on Friday. "Additionally, every dollar that Colorado hands out for free health care for illegal immigrants is money that can't be spent on seniors and rural hospitals." Newsweek reached out to Polis' office for comment. What Happens Next Debate in other states, such as New York and Washington, suggests that similar policy shifts could spread. Democratic governors pointed to financial constraints and anticipated federal funding cuts as primary reasons for reversing course. Pressures from federal proposals, such as a Trump-endorsed bill to reduce Medicaid support for states offering coverage to undocumented immigrants, are shaping state policies. States like New York and Washington are reviewing their own policies, signaling that further changes may be forthcoming as budget negotiations and federal actions continue.

Business Wire

2 hours ago

• Business Wire

Archeus Technologies Receives FDA Clearance of Investigational New Drug Application for ART-101 in Development for the Treatment of Prostate Cancer

MADISON, Wis.--(BUSINESS WIRE)-- Archeus Technologies, a company developing radiopharmaceutical therapies for the treatment of patients with cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ART-101, a novel receptor-based targeting small molecule that Archeus has developed for the imaging and treatment of prostate cancer. This IND clearance enables Archeus to initiate a Phase 1 clinical trial in men with metastatic castration-resistant prostate cancer (mCRPC), which is expected to start later this year. ART-101 was discovered and developed by Reinier Hernandez, Ph.D., assistant professor of medical physics at the University of Wisconsin–Madison, with robust development support from the Wisconsin Alumni Research Foundation. The therapy targets prostate-specific membrane antigen (PSMA), similar to several FDA-approved imaging and therapeutic agents. However, preclinical data demonstrates that ART-101 exhibits higher tumor uptake and retention, as well as lower normal tissue and salivary gland uptake, relative to current FDA-approved PSMA-targeting agents. Archeus plans to evaluate ART-101 as a theranostic radiopharmaceutical agent with the potential to deliver alpha particle-emitting isotopes with greater efficacy and safety compared with current standards of care. 'This IND clearance marks an important milestone for Archeus as we prepare to initiate the first of multiple clinical trials set to begin this year from our broader portfolio of differentiated radiopharmaceutical assets for difficult-to-treat cancers,' said Evan Sengbusch, Ph.D., chief executive officer of Archeus Technologies. 'ART-101 represents a promising approach to targeting PSMA-positive prostate cancer with the potential to deliver meaningful clinical benefit and reduced side effects for patients. We are eager to begin evaluating ART-101 in patients to better understand its full therapeutic potential.' In addition, Archeus received IND clearances in October 2024 for its lead therapeutic candidate, ARC-706, and companion diagnostic, ARC-166. The company plans to advance the two assets - together as a theranostic pair - into clinical development this year. Archeus is developing ARC-706 for combination use with certain validated immunotherapies across a range of cancer types. Preclinical data indicate that this radiopharmaceutical agent and treatment paradigm may produce curative responses, as well as immune memory against cancers that are otherwise resistant to these immunotherapies. About Archeus Technologies Archeus Technologies is a company developing radiopharmaceutical therapies for some of the most difficult-to-treat cancers. Starting with its Phase 1-ready therapeutic candidate, ARC-706, the company has assembled a growing pipeline of differentiated radiopharmaceutical therapy agents and companion diagnostic assets with the potential to provide curative responses to patients with advanced cancer. Archeus is led by an executive team with proven radiopharmaceutical expertise and a demonstrated record of advancing innovative agents from discovery through clinical development. In addition, Archeus has a long-standing strategic collaboration with the University of Wisconsin–Madison (UW), a global leader in radiopharmaceuticals and theranostics. To learn more, visit